CD274 and neoplasm: In fact, preclinical trials using a combination therapy that include check point inhibitors showed the A2AR compound AZD4635 induced anti-tumor immunity alone and in combination with anti-PD-L1 (durvalumab) by reversing adenosine-mediated T cell suppression and boosting antitumor immunity [20].